Clinical Trial Update: Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease [Phase 4]

View source ↗

Summary

Clinical trial update describing a Phase 4 study evaluating the efficacy and safety of the Ledipasvir/Sofosbuvir fixed-dose combination for 12 weeks in patients…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• HARVONI (Ledipasvir and Sofosbuvir)

Snippet

Sponsor: Peter J. Ruane, M.D., Inc. | Conditions: Chronic Hepatitis C | Phase 4 | Status: UNKNOWN